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Abstract 
Inhibitor formation against coagulation factor VIII (FVIII) is an unresolved serious problem in 
replacement therapy for the X-linked bleeding disorder hemophilia A. Although FVIII inhibitors 
have been extensively studied, much of the basic mechanism of this immune response remains 
to be uncovered. Within the NHLBI State of the Science Workshop on Factor VIII Inhibitors, 
Working Group 3 identified three scientific priorities for basic and translational research on FVIII 
inhibitor formation. These include activation signals and immune regulation that shape the 
response to FVIII (including innate immunity, microbiome, adaptive immunity and regulatory T cell 
studies in humans); utility of animal models and non-animal approaches (in silico, genetic, single 
cell/sorted population ‘omics, in vitro) to help predict inhibitor formation and identify novel 
therapeutics; and impact of the source of FVIII, its structure, and von Willebrand factor on 
immunogenicity and tolerance. Early interactions between FVIII and the immune system, 
biomarker development, and studies in different patient groups (previously treat or untreated, with 
or without inhibitor formation, patients undergoing immune tolerance induction or gene therapy) 
deserve particular emphasis. Finally, linking basic to clinical studies, development of a repository 
for biospecimens, and opportunities for interdisciplinary research training are important 
components to solving the urgent problem of inhibitor formation.      
INTRODUCTION 
 
Inhibitor formation against coagulation factor VIII (FVIII) is an unresolved serious problem 
in replacement therapy for the X-linked bleeding disorder hemophilia A 1. Although FVIII inhibitors 
represent the perhaps best studied example of anti-drug antibody formation, much of the basic 
mechanism of this immune response remains to be uncovered. Importantly, such basic questions 
provide guidance for translational and clinical studies. For instance, one may be able to devise 
strategies that reduce the incidence of inhibitor formation, better predict which patients are likely 
to form inhibitors or to tolerize after initial inhibitor development, or develop biomarkers for early 
stages of a developing immune response or, conversely, tolerance.  
It is known that the activation of B cells that leads to the production of inhibitors requires 
help from CD4+ T cells (Fig. 1). Critical co-stimulatory pathways for dendritic cell (DC) – T cell 
and B cell – T cell interactions include CD86-CD28, ICOS-ICOSL and CD40-CD40L 2. Regulatory 
T cells (Tregs) are able to suppress antibody formation. The role of CD4+CD25+FoxP3+ Tregs in 
tolerance to FVIII has been described in numerous studies, while latency associated peptide 
(LAP) expressing Tregs are more typical in oral tolerance to FVIII, representing various 
approaches to achieve tolerance 3-6. Presumably, innate immune signals that may derive from 
tissue damage or molecular patterns associated with pathogens trigger initiation of these adaptive 
immune responses. For example, bacterial lipopolysaccharide (LPS) functions as an adjuvant 
and enhances FVIII inhibitor formation in hemophilic mice. Certain types of macrophages and 
marginal zone B cells have also been implicated in initial FVIII uptake in lymphoid organs 7,8. How 
these innate factors and cell types [including innate immune and antigen presenting cells (APCs)] 
interact during the transition from initial innate immune signaling to the adaptive immune response 
remains to be defined.  
Liver sinusoidal endothelial cells (LSEC) are the predominant natural site of FVIII 
biosynthesis, although other endothelial cells (such as lymphatic and other fenestrated 
endothelium) also contribute 9-11. Recombinant FVIII is made in various mammalian cell lines 
(none of which are endothelial cells), and current gene therapies target hepatocytes for FVIII 
expression. The latter can induce immune tolerance, although recent literature suggests that 
targeting LSEC, as compared to hepatocytes, may better induce tolerance, perhaps owing to their 
ability to promote induction of Treg 5,6,12.  
Potential reasons for differences in immunogencity of FVIII produced by varying cell types 
need to be better addressed. Interestingly, FVIII produced in cultured cells with different N-
glycosylation showed differences in inhibitor formation in hemophilic mice 13. Von Willebrand 
Factor (vWF), which binds to FVIII and is critical for its half-life in the circulation, has been shown 
in several studies to affect FVIII immunogenicity, possibly by changing APC and/or endothelial 
cell FVIII uptake 14. Receptors on macrophages and sinusoidal endothelial cells, such as the 
recently identified stabilin-2, regulate this process 15. Thus, the structure of FVIII (including 
posttranslational modifications), its interactions with other plasma proteins and cell surface 
receptors, and its site of synthesis all impact its immunogenicity; but, there is more to be learned 
about these different mechanisms and how they interact. Recent autoimmune disease studies 
documented that the gut microbiome can also play a role in regulating antibody formation 16. 
Antigens in the systemic circulation are also taken up by APCs in the gut associated immune 
system. The role of the microbiome in immunity to FVIII has not yet been determined.  
There has been progress in the identification of risk factors for inhibitor formation, including 
polymorphisms in the promoter regions of genes related to immune functions 17. The underlying 
F8 mutation is an expected factor since greater loss of coding information reduces the likelihood 
of central tolerance. How much the major histocompatibility complex (MHC) contributes is less 
clear, with some studies however providing evidence for a correlation between MHC and inhibitor 
formation. Several CD4+ T cell epitopes (and the HLA-class II molecules that present them) have 
been identified. Some studies suggest a large epitope repertoire, while others point to a more 
restricted set of epitopes that actually drive the T cell response during inhibitor formation 18,19. 
Substantially more information about genetic factors is expected to emerge from the nationwide 
My Life Our Future initiative (www.mylifeourfuture.org), which already resulted in the genotyping 
of several thousand patients with hemophilia in the US 20.   
It is noteworthy that multiple animal models are available for pre-clinical studies in 
hemophilia 21. These include hemophilia A mice with targeted deletions of F8 exons 16 or 17, 
bred on different genetic strain backgrounds, in addition to a total gene deletion hemophilia A 
mouse on a C57BL/6 background. Transgenic hemophilia A mice expressing certain human HLA 
molecules are also available. Hemophilia A dogs, e.g. with a F8 intron 22 inversion analogous to 
the most common mutation in humans, are a well characterized large animal model. Hemophilic 
animals of other species have also been identified but not as widely studied.    
 
MATERIALS AND METHODS 
Working group membership: 
A group of 17 individuals with scientific expertise in diverse areas were assembled (see 
Table 1). Their areas of research and expertise included FVIII biochemistry, adaptive and innate 
immunity, immune regulation and tolerance, product development, in silico modeling, systems 
biology, animal models, genetics, genomics, clinical research, gene therapy, and microbiome 
studies, as well as patient treatment and advocacy.   
 
Plan of execution:  
The Working Group initially identified a large number of potential goals for basic and 
translational research on FVIII inhibitor formation and then developed a strategy for scientific 
prioritization. Ultimately, 3 scientific priorities were identified. Subgroups were formed to develop 
the details of each priority. Subsequently, the entire Working group weighted each scientific goal 
based on required effort and potential impact and identified approaches, methods/technologies, 
and models to complete the studies. Strategies to connect and embed mechanistic research into 
clinical studies and clinical trials were discussed. Requirements and strategies for biospecimen 
collection and distribution were developed. Finally, opportunities for interdisciplinary research 
training were identified.      
RESULTS AND DISCUSSION 
Scientific priorities and implementation strategies for basic research: 
Significant gaps exist in the knowledge of the mechanism of the immune response to FVIII, 
and multiple factors affect FVIII immunogenicity. Therefore, tackling this complex scientific 
problem requires scientific priorities, and implementation of strategies for acquiring an actionable 
understanding of FVIII immunogenicity and the biology of both host immunity and tolerance. To 
aid in the determination of scientific prioritization, different aspects of potential research goals 
were evaluated by Working Group 3 for their potential impact to the field relative to the degree of 
effort and cost necessary. Similarly, the advantages and limitations of human and model studies 
(animal, cell, in silico) were taken into consideration. Finally, the sequence of research pathways 
was addressed. For example, for human studies, genetic and immune characterization studies 
are low effort but potentially high impact when analyzing samples from previously treated patients 
(PTPs), for whom blood draw volumes are less limiting. These studies need to be performed prior 
to studies in previously untreated patients (PUPs) to help determine best use of limited sample 
volumes (Fig. 2). It should be recognized that immunological studies in the 70-80% of PTP who 
have not formed inhibitors are similarly important to immune response mechanisms in inhibitor 
patients, because these will help delineate why the response is directed to tolerance or antibody 
formation, aid in the identification of biomarkers, and potentially lead to interventions that favor 
immune tolerance induction and thus prevent inhibitor formation. Such studies will also improve 
prediction of risk of inhibitor formation for individual patients.    
 
Scientific priorities for basic and translational research on FVIII immunogenicity: 
Ultimately, the scientific priorities for basic and translational research were divided into 3 
priorities that approached immunity to FVIII from two aspects: (1) mechanisms of the initial 
immune response upon FVIII exposure that results in peripheral tolerance or inhibitor 
development and (2) mechanisms by which the immune system responds to FVIII exposure with 
immune tolerance induction (ITI) following initial inhibitor development. The latter may be based 
on traditional ITI protocols or emerging gene therapies. In addition, potential modifiers of the 
immune response, such as the microbiome, glycosylation patterns, and route of FVIII exposure 
(intravenous, subcutaneous, cellular production following gene therapy) were considered. 
Specifically, the following three scientific priorities were identified: (1) Activation signals and 
immune regulation that shape the response to FVIII (including innate immunity, microbiome, 
adaptive immunity and Treg studies in humans; Table 2); (2) Utility of animal models and non-
animal approaches (in silico, genetic, omics, in vitro) to help predict inhibitor formation and identify 
novel therapeutics (including single cell approaches; Table 3); and (3) Impact of the source of 
FVIII, its structure, and vWF on immunogenicity and tolerance (including the impact of gene 
therapy on FVIII tolerance versus immunogenicity, considering the choice of vector, transgene 
and cellular target; Table 4).    
Within priority #1, particular emphasis should be placed on early interactions between 
FVIII and the immune system, which are shaped by innate immune cells, signals from tissue and 
potentially microbiome, and FVIII structure/biochemical aspects. Furthermore, biomarkers that 
can be used to detect the immune response early and that correlate with a subsequent adaptive 
response, resulting in inhibitor formation, are currently lacking.  
Study designs to address these priorities would need to consider several key questions: 
What are the critical genes and pathways that shape the immune response to FVIII (including 
innate immunity and microbiome effects), and how can they be targeted to reduce immunogenicity 
to FVIII? How can non-animal approaches be used to predict and model inhibitor formation and 
tolerance induction? What are the advantages and disadvantages of different animal models? For 
example, one may be able to develop or incorporate additional mouse strains into model studies 
to assess genetic modifiers of the immune response. How does the site of FVIII expression, its 
structure, and vWF determine immunogenicity and tolerance? How can this knowledge be applied 
to gene therapy and to the selection of strategies to induce immune tolerance? What experimental 
models and novel technologies are available and being used by groups such as the Immune 
Tolerance Network (ITN)? How can they be utilized to investigate FVIII immunogenicity and 
mechanisms of tolerance? These latter questions lead to another critical aspect in study design, 
the incorporation of basic research into clinical and translational studies in order to maximally 
benefit patients.    
 
Models for the integration of basic science into clinical studies/translational research: 
Studies on immune mechanisms can be integrated into clinical antenatal/neonatal cohort 
studies, into lifespan studies on inhibitor development, and into clinical trials, including 
accompanying biospecimen procurement that ideally would be handled by a central biorepository 
and processing center 22-24. This center would do as much of the processing on site as possible 
using standardized protocols and disperse samples to different investigators to minimize 
processing inconsistency. Ability to link the respective specimens to key clinical events will greatly 
enhance their utility. The framework and timing of biospecimen procurement should be informed 
by the scientific priorities and then integrated into the different trials and observational studies to 
maximize the scientific data that can be obtained from a limited number of subjects. Because of 
the relatively small number of PUPs, and the challenges of numbers needed for adequate 
statistical power, it may be advantageous to implement a collaborative network with independent 
oversight from an expert steering committee. Such a structure could then triage and prioritize 
basic research questions and facilitate the collaborative distribution of samples from the limited 
pool of patients. A possible model for such a design is the APOLLO (APOL1 Long-term Kidney 
Transplantation Outcomes Network) network and studies funded by the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK). All participating sites would be required 
to pursue independent research while contributing DNA or other biological samples to the 
consortium from their site or a partner clinical site. Individual clinical centers that receive funding 
from other community studies would be expected to contribute as many types of samples as 
possible given their available resources. Given recent advances in gene therapy as a potential 
cure for hemophilia, it would be most advantageous to also incorporate analysis of immune 
responses to FVIII in gene therapy trials and work, potentially with industry partnerships, toward 
a clinical trial on reversal of inhibitors by gene therapy (Fig. 2) 22. This will also help prepare gene 
therapy trials that aim to induce tolerance in patients with inhibitors. Again, an important aspect 
of clinical development of any novel approach to eradication of inhibitors will be identification of 
biomarkers for tolerance induction to FVIII.   
For any combined basic science/clinical study, the requirements and timelines for 
collection of biospecimens are important. For instance, a feasible schedule for blood sample 
collection in PUPs could be prior to and one day following initial FVIII exposure, followed by 
periodic sampling during the first 50 exposure days and then further albeit less frequent sampling 
throughout the lifespan. Samples from PTPs should include those who never developed an 
inhibitor, have a persistent inhibitor, or were successfully tolerized after inhibitor formation. 
Samples from inhibitor patients should be collected at the time of inhibitor formation, prior to 
initiation of ITI, 2-4 weeks after starting ITI, and then at regular intervals, such as every 3 months 
until tolerized. For microbiome studies, fecal samples from mothers should be collected at the 
end of the first, second and third trimester for 16S or metagenomics analysis. Ideally, the placenta 
should also be analyzed after birth (Fig. 3). As soon as possible after birth, meconium should be 
collected. Feces from the infant should then ideally be sampled every month in the first year after 
birth. Any factor that might affect the microbiome should be noted. Antibiotic use in the mother or 
infant, breast milk versus formula diet, and post-natal exposure to pets or farm animals are among 





Challenges and models for cross-disciplinary research: 
Advancing basic science and clinical immunology in the field of FVIII inhibitor formation 
would greatly benefit from recruitment of scientists from various disciplines, including but not 
limited to biochemistry, genetics, genomics, bioinformatics, and immunology (Fig. 4). The 
implementation of such interdisciplinary research is always a challenge. A recent example of a 
model for this type of collaborative research is the NHLBI U54 FVIII Centers initiative 
(grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-014.html) that allow training opportunities in 
newly established cross-disciplinary settings. These three centers will characterize the functional 
repertoire and ontogeny of FVIII humoral immunity across species, study the in vivo mechanisms 
of FVIII immunity and the influence of the host microbiome; define the structural basis for FVIII 
immune recognition and related immunobiology, and study the immunopharmacology of FVIII 
bioengineering and gene therapy; study the role of glycosylation in inhibitor formation, and 
characterize genetic effects on FVIII glycosylation patterns and inhibitor formation. Importantly, 
these centers include skill development cores that aid in the training of interdisciplinary scientists 
that will be well equipped to develop future studies on immunogenicity of FVIII and tolerance.   
For other efforts, such as clinical trials, industry support is critical. However, how to 
integrate industry goals with core scientific goals remains a challenge. However, an organization 
such as the NIH Foundation could facilitate industry’s support of basic scientific research goals. 
Regardless of funding opportunities and the structures in place, consistent engagement of 
scientists whose primary focus is in other areas will require strong partnership between FVIII 
researchers and these colleagues. Only then one can meet the challenges of keeping up with 
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Table 1. Members of Working Group 3 organized by their respective expertise. 
 
Table 1    Working Group 3 Members  
Expertise Investigator Affiliation 
Molecular Biology & 
Omics 
Cheryl Winkler, PhD NCI 
Factor VIII 
Biochemistry 
Peter Lenting, PhD 





Bernard Khor, MD, PhD 
Kate Pratt, PhD 
Benaroya Research Institute 
Uniformed Services University 
Antigen Generated 
Peptide Expertise 
Betty Diamond, MD 
Jean Marie Saint-Remy, MD, 
PhD  
 
Feinstein Institute for Medical 
Research 
KU Leuven, Belgium 
 
Gene Therapy 
Animal and Ex Vivo 
Models 
Valder Arruda, MD, PhD 
Wadie Bahou, MD 
David Lillicrap, MD 
Roland Herzog, PhD 
Children’s Hospital of Philadelphia 
Stony Brook University 
Queen’s University, Kingston, ON 
Indiana University 
Microbiome Josef Neu, MD University of Florida 
In Silico Protein 
Modeling 






David Wraith, MD, PhD 
 








Patient Community & 
Advocacy; Treatment 
 
Glenn Pierce, MD, PhD 
Shannon Meeks, MD 
Scientist, NHF, WFH 
Emory University 
  
Table 2: Scientific priority #1: Activation signals and immune regulation that shape the 
response to Factor VIII (FVIII) 









Studies in murine models: 
• Side-by-side comparison of mice of different strain
backgrounds
• Parameters that affect the response, such as glycosylation
patterns or microbiome
• Biomarker development




• Comparison of innate immunity parameters in patient
subpopulations
• Biomarker development (cytokines, cellular, expression
signatures)
• Flow panels to include both activating and regulatory B cell
(Breg) and T cell(Treg) phenotypes, such as Th2 or Th17 cells
that might be seen in allergic or autoimmune responses
• Maternal microbiome studies
• Studies early in life through first year after birth






• Diverse group of genetic backgrounds with the same F8
mutation in mice to study genetic effects
• Improved (humanized) models
• Animal model of ITI is desirable
Modest/high 
Human studies: 
• Immune phenotyping by flow cytometry; biomarker
development
• Improved T cell epitope mapping
• Activation markers in response to FVIIII; transcriptome and
single cell footprints
• Development of technologies to analyze small sample sizes or
rare cells such as circulating memory B cells and long-lived
plasma cells
• Biomarker development (high/high cellular, expression





Human and animal studies: 
• Biomarkers of effective immunotherapy with FVIII
• Gene expression signatures in antigen-specific T cell
populations during immunotherapy
• Novel methods for tolerance induction
• Experimental models for assessing tolerance induction
• Treg characterization and potentially other regulatory cells
such as Bregs and M2 IL10 producing DCs




Table 3: Scientific priority #2: Utility of non-animal approaches (in silico, genetic, 
omics, in vitro) to help predict inhibitor formation 
 
Scientific priority #2: Utility of non-animal approaches (in silico, genetic, omics, in vitro) to 
help predict inhibitor formation 
Overall study goals Detailed study goals Effort/impact 
In vitro assays for 
antigen presentation 
and T cell activation 
• FVIII antigen presentation assays 
• Novel methods for TCR, BCR repertoire analysis 
• Mapping of T-cell and B-cell epitopes (experimental 
and in silico predictions) 
• Antigen-specific responses of Tregs as well as T-
effectors 
• Analogies to both autoimmune disorders and 
vaccine studies 
• Roles of anergy, deletion, Treg in initiation of anti-
FVIII immune response and in ITI-refractive 
patients 
• Coordination with investigators doing animal 
model studies 
• Natural history/phenotyping and potential targets 
for peripheral tolerance: CD4+ T cells, long-lived 







immune response to 
FVIII 
• Genomics studies within MLOF projects 
• Transcriptomics studies on whole-blood RNA and 
RNA from defined subsets of cells, such as CD4+ T 
cells, including single-cell analyses.  
• TCR/BCR repertoires of single cells 
• Proteomics studies to quantify protein expression 
levels and identify/quantify post-translational 
modifications; improved proteomic profiling of 
serum, plasma, whole blood, and cell lysates  
• Epigenomics studies on sorted cell populations  
High/high 
Bioinformatics and in 
silico modeling of 
antigen presentation 
• Establish collaborations between bioinformatic 
experts and immunologists 
• Risk factors for failure to respond to ITI may be 
identifiable by retrospective biostatistical analysis 
• In silico predictions of epitopes currently have 
limitations, but can still be useful provided that 
larger and more quantitative data sets can be 
obtained 
• Determining the total number of clinically relevant 
epitopes would be desirable, although 
polymorphisms/mutations in HLA result in patient-
specific effects  
• Deimmunization strategies (i.e. removal of 
immunogenic epitopes) will benefit from expanded 




*there was much 
debate within WG3 
about pros/cons of 
this approach, with 
strong opinions that 
it would be high 
impact and strong 
opinions it would be 
low impact 
  
Table 4: Scientific priority #3: How does the site of Factor VIII (FVIII) expression, its 
structure, and von Willebrand factor (vWF) determine immunogenicity and tolerance 
 
Scientific priority #3: How does the site of FVIII expression, its structure, and vWF 
determine immunogenicity and tolerance 
Overall study goals Detailed study goals Effort/impact 
FVIII expressed in 
gene therapy 
• More detailed immunological studies in patients 
participating in current and future gene therapy 
trials are desirable (e.g. evidence for immune 
regulation or small, non-clinically evident changes 
in the immune response to FVIII) 
• Work toward gene therapy trials in inhibitor 
patients, in particular those who failed ITI 
• Define innate immunity to AAV and lentiviral 
vectors 
• Study immunogenicity of altered (bioengineered) 





• Effect of FVIII molecules with altered interactions 
with vWF 
• Modulation of antigen uptake, presentation and 
clearance through scavenger receptors by vWF 
• Effect of de-targeting from endogenous vWF in new 
products currently in development  
• Development of molecules with more stable 
binding to vWF    
High/modest to 
high 
FVIII molecules with 
altered structure 
• Immunoglobulin can have a tolerogenic effect 
Therefore, Fc fusion proteins may aid in tolerance 
induction, e.g. during ITI or in utero 
• Study a potential influence of PEGylation on FVIII 
immunogenicity 
• Assess the immunogenicity of engineered FVIII 
molecules, in particular those with amino acid 







Figure 1: Mechanisms of antibody formation against FVIII. Innate immune signals (lower half) 
may lead to activation of FVIII-specific CD4+ T helper cells, and ultimately in B cell activation and 
formation of inhibitors. Long-term inhibitor production may occur in plasma cells, while regulatory 
T cells (Treg) have the capacity to down-regulate the response and promote tolerance.   
 
Figure 2: Comprehensive collection of blood samples in various hemophilia A patient populations 
undergoing FVIII replacement therapy; including previous untreated patients (PUPs), previously 
treated patients (PTPs), patients with and without inhibitors, patients undergoing immune 
tolerance induction (ITI), and patients being treated with gene therapy.   
 
Figure 3: Potential timelines for collection of microbiome samples from pregnant mothers and 
newborns/infants with hemophilia A. Child development cartoon adopted from Pediatr Rev. 
1997;18:224–242.  
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